Obinutuzumab-related adverse events: A systematic review and meta-analysis.
CD20
adverse events
obinutuzumab
rituximab
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
23
11
2020
received:
07
10
2020
accepted:
24
11
2020
pubmed:
1
12
2020
medline:
22
4
2021
entrez:
30
11
2020
Statut:
ppublish
Résumé
Rituximab, the first anti-CD20 monoclonal antibody, has dramatically improved outcomes for patients with B-cell lymphoproliferative disorders. Obinutuzumab was developed to potentiate activity and overcome resistance to rituximab. Clinical data suggest that obinutuzumab is superior to rituximab in follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Yet, it has increased toxicity. This systematic review and meta-analysis compiled all randomized controlled trials (RCTs) comparing obinutuzumab-based regimens with rituximab-based regimens to better assess their toxicity profile. Primary outcome was grade 3-4 infections; secondary outcomes included any adverse events (AE), grade 3-4 AE, drug discontinuation rate, and 3-years mortality. Relative risks (RRs) were estimated and pooled using a fixed-effect model, unless there was significant heterogeneity, in which case a random-effects model was used. Our comprehensive search yielded five RCTs conducted between 2009 and 2014, including 4247 patients. The trials included FL patients, CLL and diffuse large B cell lymphoma. Monoclonal antibodies were given with different chemotherapy regimens (in four trials) or as monotherapy (in one trial). The point estimate favored increase in both grade 3-4 infections rate (RR 1.17 [95% CI, 1.0-1.36]) and any AE rate (RR 1.05 [95% 1-1.1]) with obinutuzumab, although this was not statistically significant. There was a significantly increased rate of grade 3-4 AE (RR 1.15 [95% CI, 1.09-1.2]), as well as grade 3-4 toxicities including thrombocytopenia (RR 2.8 [95% CI, 1.92-4.06]), infusion related reactions (RR 2.8 [95% CI, 2.16-3.64]) and cardiac events (RR 1.65 [95% CI, 1.11-2.46]). There was no significant difference in grade 3-4 anemia and neutropenia nor in the 3-year mortality rate. The point estimate favored increase in discontinuation rate due to AE with obinutuzumab, although without statistical significance (RR 1.24 [95% CI, 1.0-1.54]). In conclusion, physicians need to weigh the clinical benefits of this agent against higher toxicity.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
obinutuzumab
O43472U9X8
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-221Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Armitage JO , Longo DL . Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood. 2016;127:2804-2808.
Hiddemann W , Kneba M , Dreyling M , et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732. https://doi.org/10.1182/blood-2005-01-0016
Marcus R , Imrie K , Solal-Celigny P , et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586. https://doi.org/10.1200/JCO.2007.13.5376
Pfreundschuh M , Kuhnt E , Trümper L , et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-Year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022.
Pfreundschuh M , Schubert J , Ziepert M , et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116. https://doi.org/10.1016/S1470-2045(08)70002-0
Rezvani AR , Maloney DG . Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2):203-216.
Freeman CL , Sehn LH . A tale of two antibodies: Obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29-45.
Bologna L , Gotti E , Manganini M , et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186:3762-3769.
Marcus R , Davies A , Ando K , et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344.
Goede V , Fischer K , Engelke A , et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. Leukemia. 2015;29(7):1602-1604.
Goede V , Fischer K , Dyer M , et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the Cll11 Study. Paper presented at: EHA 2018; EHA Library. Goede V. 15th June 2018;215923.
Vitolo U , Trněný M , Belada D , et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529-3537.
Casasnovas RO , Salles GA , Oberic L , et al. Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1-3 DLBCL patients (<60 years): Third planned interim and final analyses of the GAINED trial. Blood. 2017;130:190.
Focosi D , Tuccori M , Maggi F . Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. Rev Med Virol. 2019;29(6):e2077.
Higgins JPT , Green S , eds. Cochrane handbook for systematic reviews of interventions: version 6. 2019. The Cochrane Collaboration Available at https://training.cochrane.org/handbook/current
US Department of Heath and Human Services. National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Julian H , James T . Review Manager, Version 5.2 for Windows. The Cochrane Collaboration, Oxford, UK.
DerSimonian R , Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
Sehn LH , Goy A , Offner FC , et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467-3474.
Freeman CL , Morschhauser F , Sehn L , et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126(24):2646-2649.
Walter HS , Jayne S , Mensah P , et al. Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12. Blood Cancer J. 2016;6(6):e435.
Hiddemann W , Barbui AM , Canales MA , et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395-2404.
Pfreundschuh M , Müller C , Zeynalova S , et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123(5):640-646.
Ternant D , Hénin E , Cartron G , Tod M , Paintaud G , Girard P . Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol. 2009;68(4):561.
Zhu N , Zhang D , Wang W , et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
Scarfò L , Chatzikonstantinou T , Rigolin GM , et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354-2363.